LLY Stock Recent News
LLY LATEST HEADLINES
In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy increase in value.
The big pharma sector is one that's generally fallen out of favor for many investors over the past few decades, as large healthcare companies have seen slower growth and consolidation hasn't generally provided the kind of upside investors had grown accustomed to over the latter half of the past century.
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Artificial intelligence (AI) platforms have been enjoying the spotlight since the original release of ChatGPT in late 2022 and have started gaining increasing traction among investors for apparently outperforming a significant portion of professional managers.
Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory" in its financial statements, a filing showed on Wednesday.
Review Lilly's (LLY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in obesity.
Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in obesity.
Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are transforming the company. Lilly now has an obligation to take on other challenging diseases like Alzheimer's, ALS and chronic pain, said the the company's Chief Scientific Officer Dan Skovronsky.
Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more potent drugs are two areas where Lilly is focusing.